Concepedia

Author

Julio del Río-Garma

Complejo Hospitalario de OurenseORCID

Also Known As

J del Rio Garma, J del Río Garma, J. Del Río, J. Del Río‐Garma, J. del Río, J. del Río Garma, Julio Del Rio Garma, Julio Del Rio-Garma, Julio Del Río-Garma, Julio Del Río-Garma

39

Publications

508

Citations

13

H-Index

10

Concepts

All Affiliations

Complejo Hospitalario de OurenseBanc de Sang i TeixitsHospital Clínic de BarcelonaHospital Clínico Universitario de ValenciaHospital Universitario Central de Asturias
JD

About

Julio del Río-Garma is an author at Complejo Hospitalario de Ourense specializing in thrombosis, medicine, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

106

2

Hematology

3

3

47

3

Pathology

2

2

31

4

Epidemiology

1

1

13

5

Vascular Disease

1

1

18

Julio del Río-Garma

×

11

Publications

297

Citations

10

H-Index

YearCitations

Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study

Javier de la Rubia, Federico Moscardó, María Gómez,

Transfusion and Apheresis Science

2010

59

Methylene blue‐photoinactivated plasma <i>versus</i> quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study

Julio del Río-Garma, Alberto Álvarez‐Larrán, Clara Martínez,

British Journal of Haematology

2008

57

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

Cristina Pascual, María Eva Mingot‐Castellano, A Fuentes,

Blood Advances

2022

49

Incidence, diagnosis, and outcome of immune‐mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura

Cristina Pascual, Julio del Río-Garma, Javier de la Rubia,

Journal of Clinical Apheresis

2021

21

Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)

Paul Coppo, Michaël Bubenheim, Y. Benhamou,

EClinicalMedicine

2025

21

Multicentric evaluation of the new HemosIL Acustar<sup>®</sup> chemiluminescence ADAMTS13 activity assay

Cristina Pascual, Jorge Martínez Nieto, Teresa Fidalgo,

International Journal of Laboratory Hematology

2020

20

Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group

Enric Contreras, Javier de la Rubia, Julio del Río-Garma,

Medicina Clínica (English Edition)

2015

18

Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment

Alberto Álvarez‐Larrán, Julio del Río-Garma, Misericòrdia Pujol,

Annals of Hematology

2009

16

Mortality in acquired thrombotic thrombocytopenic purpura in the pre-caplacizumab era

Julio del Río-Garma, Sabela Bobillo, Javier de la Rubia,

Annals of Hematology

2021

13

ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

María Eva Mingot‐Castellano, Faustino García‐Candel, Jorge Martínez Nieto,

Blood

2024

13

Page 1